Amicus Therapeutics, Inc. (FOLD)

Amicus Therapeutics, Inc. was a global biotechnology company focused on medicines for rare metabolic diseases. It was founded in 2002 and was historically based in New Jersey, and in later years it listed Philadelphia, Pennsylvania as its headquarters. Its common stock traded on Nasdaq under the symbol FOLD following its initial public offering in 2007.

Its first commercial product was Galafold, an oral precision medicine containing migalastat for adults with Fabry disease who have amenable genetic variants. Galafold was approved in the European Union in 2016 and in the United States in 2018, and it grew into the company's main source of revenue.

The company's second major franchise treated Pompe disease, a rare inherited disorder that affects muscle function. This was a two-component regimen of cipaglucosidase alfa (Pombiliti) with miglustat (Opfolda), which received regulatory approvals in Europe and the United States in 2023. The company also explored gene therapy and enzyme replacement approaches for other rare conditions through research collaborations with academic institutions.

Co-founder John Crowley led Amicus as chief executive for many years, and later the company was led by Bradley Campbell. Over time Amicus built a commercial presence in many countries, with revenue mainly from Galafold and Pombiliti and Opfolda.

In December 2025, BioMarin Pharmaceutical announced that it would acquire Amicus for $14.50 per share in cash, an equity value of about $4.8 billion. BioMarin, a rare disease company, said the transaction would add Galafold and the Pompe therapies to its portfolio.

The merger required approval from Amicus stockholders and regulatory clearances, and was completed in April 2026. At closing, each share of Amicus common stock was converted into the right to receive $14.50 in cash.

A Form 25 was filed on April 27, 2026 to remove the common stock from listing on Nasdaq, and Amicus became a wholly owned subsidiary of BioMarin.